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Global birth prevalence and mortality from 
inborn errors of metabolism: a systematic 
analysis of the evidence
Background Inborn errors of metabolism (IEM) are a group of over 
500 heterogeneous disorders resulting from a defect in functioning of 
an intermediate metabolic pathway. Individually rare, their cumulative 
incidence is thought to be high, but it has not yet been estimated glob-
ally. Although outcomes can often be good if recognised early, IEM car-
ry a high fatality rate if not diagnosed. As a result, IEM may contribute 
significantly to the burden of non-communicable childhood morbidity.
Methods We conducted a systematic literature review of birth preva-
lence and case fatality of IEM globally, with search dates set from 1980 
to 2017. Using random-effects meta-analysis, we estimated birth prev-
alence of separate classes of IEM and all-cause IEM, split by geograph-
ical region. We also estimated levels of parental consanguinity in IEM 
cases and global case fatality rates and resultant child deaths from all–
cause IEM.
Findings 49 studies met our selection criteria. We estimate the glob-
al birth prevalence of all-cause IEM to be 50.9 per 100 000 live births 
(95% confidence intervals (CI) = 43.4-58.4). Regional pooled birth 
prevalence rates showed the highest rates of IEM to be in the Eastern 
Mediterranean region (75.7 per 100 000 live births, 95% CI = 50.0-
101.4), correlating with a higher observed rate of parental consan-
guinity in studies from this area. We estimate case fatality rates to be 
33% or higher in low- and middle-income countries (LMICs), result-
ing in a minimum of 23 529 deaths from IEM per year globally (95% 
CI = 20 382-27 427), accounting for 0.4% of all child deaths worldwide.
Conclusions IEM represent a significant cause of global child mor-
bidity and mortality, comprising a notable proportion of child deaths 
currently not delineated in global modelling efforts. Our data highlight 
the need for policy focus on enhanced laboratory capacity for screening 
and diagnosis, community interventions to tackle parental consanguin-
ity, and increased awareness and knowledge regarding management of 
IEM, particularly in LMICs.
Electronic supplementary material: 
The online version of this article contains supplementary material.
journal of
health
global
As outcomes improve in many areas of the world for common infectious 
causes of child morbidity and mortality, the contribution of other less com-
mon illnesses to the burden of disease in those under 5 years old is receiv-
ing increased attention [1,2]. One group of such diseases are the ‘inborn 
errors of metabolism’ (IEM), a heterogeneous group of over 500 disorders, 
individually rare but with a likely high cumulative incidence and potential 
to result in substantial mortality or long-term morbidity [3].
Waters et al.
December 2018  •  Vol. 8 No. 2 •  021102 2 www.jogh.org •  doi: 10.7189/jogh.08.021102
V
IE
W
PO
IN
TS
RE
SE
A
RC
H
 T
H
E
M
E
 7
: E
PI
D
E
M
IO
LO
G
Y 
O
F 
 
N
O
N
-C
O
M
M
U
N
IC
A
B
LE
 C
A
U
SE
S 
O
F 
C
H
IL
D
 D
E
A
TH
S
IEM are defined as monogenic diseases resulting in deficient activity of an individual enzyme, structural 
protein or transporter molecule in an intermediate metabolic pathway [4,5]. This deficiency can pres-
ent clinically in a wide variety of ways, ranging from non-specific chronic issues such as childhood delay 
in attaining development milestones, to acute decompensation in the neonatal period with severe treat-
ment-refractory metabolic acidosis or hypoglycaemia [2]. Most disorders are treatable if diagnosed early 
but can be rapidly fatal without prompt recognition [6]. Resulting from the heterogeneity in clinical pre-
sentation, which can overlap with many other diseases, diagnosis of IEM can prove difficult, and is often 
missed. Some IEM such as phenylketonuria (PKU) have been part of newborn screening tests in many 
countries for over 30 years, however rarer conditions are often not part of routine screening [4,6]. Diag-
nosis of these conditions often requires a high index of clinical suspicion combined with relatively nov-
el sophisticated diagnostic investigations such as tandem mass spectrometry [7,8]. Diagnostic difficulty 
is more marked in low- and middle-income countries (LMICs) where access to advanced diagnostic ap-
proaches is limited due to resource constraints [9]. This is particularly of concern in areas with high levels 
of parental consanguinity, a known risk-factor for monogenic disorders such as IEM [7].
As of yet, there are no global estimates of the burden of morbidity or mortality associated with IEM, with 
IEM remaining part of the ‘other’ diseases section of estimates from the Interagency Group on Child Mor-
tality Estimation (IGME), Maternal and Child Epidemiology Estimation (MCEE) or Global Burden of 
Disease (GBD) studies, and other similar large-scale global modelling efforts [1,10]. We are of the opin-
ion that IEM likely contribute a significant proportion of this currently poorly understood subdivision of 
disease burden. For example, even based on an assumption that IEM incidence is as low as 1 in 10 000 
births globally, hypothetically, out of 140 million live births per year globally, 14 000 children will be 
born with IEM. Given known high case fatality rates, particularly in LMICs due to limitations in diag-
nosis and management, IEM would result in a large number of under 5 deaths each year [4,5]. Without 
greater understanding of the contribution of IEM to the global disease burden, both as a whole and indi-
vidually, the potential for advocacy of IEM as an important concern for policy makers and development 
of targeted screening and treatment approaches will remain severely limited. In an effort to combat this, 
we aimed in this study to provide global estimates of birth prevalence of IEM, and resultant mortality, in 
children under 5 years of age.
METHODS
Search strategy
A systematic search of published literature was performed on databases Medline, EMBASE and Global 
Health for the years 1980-2017 using the search terms shown in Appendix 1 in Online Supplementary 
Document. This was conducted in parallel by two separate reviewers to minimise risk of bias. Studies 
were evaluated using the selection criteria shown in Table 1 and case definition criteria.
IEM case definitions
Diagnoses of IEM have been based on varying newborn screening tests, including tandem mass spec-
trometry, gas chromatography, traditional enzyme assays, radiological investigations and/or clinical symp-
Table 1. Selection criteria for literature review
Inclusion criteria:
Studies published 1980-2017 globally that referred to inborn errors of metabolism (IEM) among children
Studies that directly attempted to estimate birth prevalence and/or under-5 mortality rate of all or specific classes of IEM
Studies that provided information on determinants of IEM aetiology/occurrence, consanguinity rates, clinical features, management, case fatality 
rates and/or outcomes
Exclusion criteria:
Studies that did not estimate the birth prevalence and/or under-five mortality of IEM
Studies that were review articles, viewpoints and commentaries
Studies that did not report total live births or relevant denominator from which birth prevalence and/or under-five mortality of IEM could be estimated
Studies with ambiguous study design or analysis
Studies without active follow-up periods
Studies with unclear defined or inconsistently applied case definitions.
Global birth prevalence and mortality from inborn errors of metabolism
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toms. To ensure relatively uniform approach to case definitions in this review, we checked that studies 
reported cases and deaths from all causes of IEM based on the International Classification of Diseases 
10 ((ICD-10), ie, E70-E90) and Online Mendelian Inheritance in Man (OMIM). Eight IEM classes were 
identified from studies. Other classes of IEM returned too few data points and were not included in the 
meta-analysis (Table 2).
Data extraction
To minimise risk of bias, a parallel search (and double extraction) was conducted by two independent 
reviewers (DW and DA). Data were abstracted systematically on period of study, location, WHO region, 
study population, mean age or age range, number of IEM cases, birth prevalence rates, number of deaths, 
and case fatality rates (CFR) from IEM. For studies conducted on the same study site, population or co-
hort, the first chronologically published study was selected, and all additional data from additional stud-
ies were added in subsequently.
Quality assessment
Studies were assessed for quality using a modified Grading of Recommendations Assessment, Develop-
ment and Evaluation (GRADE) framework [11]. Quality of studies was assessed under four criteria: i) 
study design – assesses adherence to standardized screening for determining IEM, and validating data 
before data entry; ii) sampling strategy – assesses if the sampling was representative of a larger popula-
tion in the region of study; iii) statistical analysis – assesses the appropriateness of statistical and analytical 
methods in determining the outcome measure/s; and iv) study limitations – assesses explicit description 
of the study limitation with reference to each of the first three criteria (study design, sampling and anal-
ysis). Studies that were graded as high, moderate, low and very low quality, respectively (see Appendix 2 
in Online Supplementary Document for details of grading). All ‘very low’ quality studies were exclud-
ed as were the majority of ‘low’ quality studies, some being included in quantitative analysis on the basis 
of well represented study designs.
Data analysis
A random effects meta-analysis (DerSimonian and Laird method) [12] was conducted on extracted crude 
birth prevalence rates for all and specific classes of IEM, and on reported numbers of IEM deaths and 
CFR. Standard errors were determined from the reported crude estimates and live births (or other rel-
evant denominators when appropriate), assuming a binominal (or Poisson) distribution. Heterogeneity 
between studies was assessed using I-squared (I2) statistics. Meta-estimates for birth prevalence rates were 
also split by WHO region. Birth prevalence and CFR meta-estimates were combined with United Nations 
Population Division (UNPD) data for the period 2015–2020 to estimate childhood deaths from IEM.
RESULTS
Our searches returned 25036 records. Following exclusion of duplicates and application of selection cri-
teria, 49 studies were included in the final analysis. Search results are shown in Figure 1.
Table 2. Classes of inborn errors of metabolism (IEM) identified from studies
IEM class ExaMplEs
Amino acid disorders Phenylketonuria, homocystinuria
Organic acid disorders Propionic aciduria, methyl malonic aciduria, isovaleric aciduria, biotinidase deficiency
Fatty acid disorders Short or medium chain acyl-coenzyme A dehydrogenase deficiency (SCAD, MCAD)
Lysosomal storage disorders Sphyngolipidoses (Fabry, Farber, Gauher and Niemann-Pick diseases), mucolipidoses, oligosaccharidoses 
(fucosidosis, mannosidosis)
Carbohydrate metabolism disorders Galactosemia, Pompe’s disease (glycogen);
Urea cycle disorders Citrullinemia, argininemia
Mitochondrial disorders Leigh syndrome
Peroxisomal disorders Zellweger syndrome, Refsum syndrome
Others* Purine and pyrimidine disorders, metal disorders, porphyria and haematological disorders, lipid disorders and 
myelin metabolism disorders
*Returned too few data points to be included in the meta-analysis.
Waters et al.
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Study characteristics
Of the 49 studies included in the analysis, 33 reported 
estimates for all classes of IEM, with the remaining 16 
studies only reporting for specific classes of IEM. The 
selected studies were from 38 countries globally. From 
the 33 studies that provided estimates for all classes 
of IEM, study period ranged from 2000 to 2014, with 
over 20 studies conducted after 2010. The majority of 
studies (n = 13) were conducted in the WHO Western 
Pacific region (WPR A-5, WPR B-8). There were seven 
studies in each of European and Eastern Mediterranean 
regions, while the American and the South East Asian 
regions had four and two studies, respectively. There 
were no studies from sub-Saharan Africa. Table 3 shows 
study characteristics for studies reporting estimates for 
all classes of IEM, study characteristics of condition-spe-
cific studies are shown in Appendix 3 and 4 in Online 
Supplementary Document.
Birth prevalence of IEM
Figure 2 shows results for the meta-analysis of all IEM, 
with an overall birth prevalence estimate of 50.9 per 
100 000 live births (live births) (95% confidence inter-
vals 43.4-58.4 per 100 000 LB).
Figure 1. PRISMA flowchart of literature search.
Figure 2. Birth prevalence of all inborn errors of metabolism (IEM).
Global birth prevalence and mortality from inborn errors of metabolism
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From the regional meta-estimates, EMR B and WPR A had the highest birth prevalence rates of all-cause 
IEM at 75.7 (95% CI = 50.0-101.4) and 73.1 (95% CI = 39.7-106.5) per 100 000 live births (LB) respec-
tively (Figure 3, plates A-C).
Meta-estimates of individual classes of IEM showed amino acidurias to have the highest birth prevalence 
with 14.7 cases (95% CI = 12.2-17.2) per 100 000 LB, followed by lysosomal storage disorders with 13.3 
(95% CI = 9.48-17.02) per 10 000 LB. Other IEM classes that reported high birth prevalence included 
organic acidurias, mitochondrial disorders, fatty acidurias and carbohydrate metabolism disorders with 
8.7 (95% CI = 7.2-10.3), 8.2 (95% CI = 5.4-10.9), 6.5 (95% CI = 5.2-7.9) and 6.2 (95% CI = 4.5-7.9) cas-
Figure 3. A. Regional meta–estimate of birth prevalence of all inborn errors of metabo-
lism (IEM). B. Regional birth prevalence rates distribution of all IEM. C. Birth preva-
lence of IEM from all causes according to study region and period.
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es per 100 000 LB, respectively. Some other notable IEM subclasses include phenylketonuria (a variant 
of amino aciduria) and medium chain acyl-coenzyme A dehydrogenase deficiency (a variant of fatty ac-
iduria) with 6.6 (95% CI = 5.3-7.8) and 5.8 (95% CI = 4.4-7.2) per 100 000 LB respectively (45% of total 
amino acidurias and 89% of total fatty acidurias respectively) .When the crude estimates of the individu-
al eight classes included in this review were pooled together (sensitivity analysis), we recorded a pooled 
estimate of 64.6 (95% CI = 48.5-81.1) cases per 100 000 LB (Table 4 & Appendix 3 in Online Supple-
mentary Document).
Parental consanguinity rates
Few studies (n = 14) reported parental consanguinity rates among cases of IEM. The overall meta-esti-
mate was 51.47 (95% CI = 30.20-72.73) percent (shown in Figure 4). From individual studies, Saudi 
Table 4. Birth prevalence of all and individual classes of inborn errors of metabolism (IEM) globally
IEM class bIrth prEvalEncE 
(pEr 100 000 lb)
confIdEncE IntErval hEtErogEnEIty
All IEM All 50.88 43.36-58.4 I-squared = 99.0%, P < 0.001
Amino acid disorders
All 14.69 12.20-17.17 I-squared = 97.8%, P < 0.001
Phenylketonuria 6.55 5.34-7.76 I-squared = 95.7%, P < 0.001
Maple syrup urine disease 1.22 0.82-1.61 I-squared = 87.3%, P < 0.001
Homocystinuria 0.41 0.20-0.63 I-squared = 81.7%, P < 0.001
Organic acid disorders
All 8.71 7.15-10.27 I-squared = 93.5%, P < 0.001
Propionic aciduria 1.07 0.73-1.42 I-squared = 90.5%, P < 0.001
Methyl malonic aciduria 1.68 1.19-2.16 I-squared = 89.3%, P < 0.001
Isovaleric aciduria 0.51 0.28-0.73 I-squared = 68.1%, P < 0.001
Biotinidase deficiency 1.64 1.02-2.26 I-squared = 90.5%, P < 0.001
Fatty acid disorders
All 6.51 5.14-7.89 I-squared = 96.2%, P < 0.001
MCAD deficiency 5.78 4.38-7.18 I-squared = 96.8%, P < 0.001
Lysosomal storage disorders All 13.25 9.48-17.02 I-squared = 98.6%, P < 0.001
Carbohydrate metabolism disorders All 6.19 4.45-7.94 I-squared = 71.6%, P = 0.002
Urea cycle disorders All 2.91 1.90-3.92 I-squared = 83.7%, P < 0.001
Mitochondrial disorders All 8.16 5.42-10.91 I-squared = 92.2%, P < 0.001
Peroxisomal disorders All 4.13 2.78-5.48 I-squared = 95.4%, P < 0.001
MCAD – medium chain acyl–coenzyme A dehydrogenase
Figure 4. Meta–estimate of consanguinity rates of inborn errors of metabolism (IEM) from 
all causes.
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Arabia, Egypt, Libya, Bahrain, Tunisia and India had the highest consanguinity rates at 92%, 88%, 86%, 
84%, 81% and 73% respectively. Lowest rates were recorded in China (1.6%), Italy (3%), Canada (6%) 
and the United Kingdom (11%).
Deaths attributable to IEM
Data on CFR were not available from the majority of studies, Table 5 shows data from studies that did 
describe CFR (n = 7). For all studies, data were reported with a denominator of life births and the length 
of follow-up of the birth cohort being studied was unclear, resultantly it was not possible to determine 
the age or age group at which deaths occurred.
Our overall meta-estimate of deaths attributable to IEM globally is 3.2 (95% CI = 1.2-5.3) per 100 000 
LB, with a corresponding CFR of 13% (95% CI = 6%21%) (Figure 5, panels A and B). AlObaidy et al re-
ported in Libya a CFR over 30 times higher than Frazier et al in the USA (22.4 per 100 000 LB compared 
with 0.7 per 100 000 LB), likely in part due to differences in diagnosis, management and overall health 
care between and middle- and high-income settings [13,36].
DISCUSSION
Main findings
This study, as far as we are aware, provides the first global estimates of the birth prevalence and mortality 
from IEM among children under 5 years of age, in an effort to increase understanding of these potentially 
important causes of global child morbidity and mortality.
The estimated birth prevalence of all IEM globally was 50.9 (95% CI = 43.4-58.4) per 100 000 LB. This 
falls within the confidence intervals of the pooled birth prevalence rates of the eight classes of IEM includ-
ed in this review (shown in Table 4) of 64.6 cases per 100 000 LB (95% CI = 48.5-81.1), adding confi-
dence to our overall estimate (see also Appendix 3 in Online Supplementary Document). Our estimate 
of all IEM globally implies 500 IEM cases for every 1 million live births globally, suggesting 70 587 (95% 
CI = 61 147-82 281) new cases of IEM per year, based on UNDP projections for live births in the period 
2015-2020 [43]. This estimate may not be representative of all world regions, as it does not include data 
from all regions and income groups, or all possible IEM classes. In addition IEM are highly susceptible 
to underestimation due to missed diagnosis (a factor we were unable to account for). It is therefore likely 
our figure represents an under-estimate.
Regional pooled birth prevalence rates showed that EMR B had the highest IEM birth prevalence rate 
of all-cause IEM at 75.7 (95% CI = 50.0-101.4) per 100 000. Although this could be a result of selection 
bias, it may also reflect this as an area with higher parental consanguinity rates which would be expected 
to report increased IEM birth prevalence [7,44]. Studies from the EMR B region showed the highest pa-
rental consanguinity rates in IEM cases of 34-93% compared with the overall pooled consanguinity rate 
of 51.47% (95% CI = 30.20-72.73%).
The estimated global deaths attributable to all-cause IEM were 3.2 (1.2-5.3) per 100 000 LB, with a meta 
estimate of CFR of 13% (95% CI = 6-21%). Again, these figures are likely to reflect an under-estimation as 
all but one study used for these estimates came from high-income countries, and none came from low-in-
come countries. It should also be emphasised many early childhood deaths from IEM occur without an 
accurate diagnosis, particularly in LMICs [4,5]. Our data suggest a CFR of IEM in high-income settings 
ranging from 2-23%, rising to 33% in middle-income countries, and possibly higher still in low-income 
countries (Table 5). Given that the vast majority of all IEM cases will occur in LMICs it may be appropriate 
to assume that 33% represents a low bound of possible estimate for overall global CFR. This CFR applied 
to our estimated birth prevalence and combined with UNPD projections would suggest 23 529 deaths 
per year from IEM (95% CI = 20 382-27 427), approximating to 0.4% of all child deaths globally [1,43].
Limitations
There are several important limitations to the conclusions of this study. Of the 49 studies selected for this 
review, only 33 studies provided estimate on all-cause IEM. These studies were focused in certain geo-
graphical areas, with no studies from low-income countries. The lack of studies from sub-Saharan Afri-
ca is of particular concern as this region has the highest number of under 5 deaths globally [1]. In addi-
tion, only seven studies were birth cohort studies (with reference denominators provided), limiting the 
Global birth prevalence and mortality from inborn errors of metabolism
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Table 5. Deaths attributable to inborn errors of metabolism (IEM)
author yEar locatIon sEttIng % consan-
guInIty
total lb IEM 
casEs
bIrth prEv/ 
105 lb
dEaths dEaths/105 
lb
casE fatalIty 
ratE (%)
AlObaidy et al [13] 2013 Libya, Tripoli Urban 86 156006 107 68.6 33 22.4 32.7
Dionisi-Vici et al [23] 2002 Italy, national survey Urban-Rural 3 5336730 1935 36.3 356 6.4 18.4
Klose et al [32] 2002 Germany Urban-Rural N/A 844575 57 6.8 8 1.0 14.0
Couce et al [35] 2011 Spain, Galicia Urban N/A 210165 137 65.2 4 1.9 2.9
Frazier et al [36] 2006 USA, North Carolina Urban N/A 944078 219 23.3 7 0.7 3.2
Schulze et al [8] 2003 Germany Urban-Rural N/A 250000 106 42.4 3 1.2 2.8
Wilcken et al [42] 2009 Australia, national Urban-Rural N/A 1551200 115 7.4 26 1.7 22.6
N/A – not applicable, LB – live birth(s)
Figure 5. A. Meta-estimate of deaths attributable to inborn errors of metabolism (IEM) 
globally. B. Meta-estimate of case fatality rates from IEM globally.
representativeness of our conclusions due to potential selection bias. It was unfortunate that no included 
studies reported clear follow-up periods, which could have allowed a more meaningful interpretation of 
mortality and CFR over the first five years of life. Additionally, some important studies that could have 
improved the quality of this review were conducted on children aged 0-14 years, without any breakdown 
of estimates by age, meaning that relevant estimates in 0-4 years could not be extracted. It is also import-
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ant to note that many studies were conducted in areas with high consanguinity rates, likely to result in a 
higher IEM prevalence than the overall global population [7,44].
Findings in context
This study highlights the need for better understanding of IEM globally to facilitate improved diagnosis 
and management, particularly in sub-Saharan Africa where no data are currently available. Further large-
scale birth cohort studies are necessary to improve knowledge on the epidemiology of this important 
group of conditions.
Despite data limitations, our study has shown IEM represent an important cause of under 5 morbidity and 
mortality. Outcomes can be markedly improved by early recognition of IEM, and so a focus on increased 
clinician awareness globally and improved access to necessary investigations is essential to avoid missed 
diagnoses [2]. Newborn screening for common IEM has proved highly effective in many settings and it 
is important that capacity is built in LMIC health systems to foster similar screening programmes [9,45]. 
Laboratory capacity may be a significant limiting factor in screening and other investigations, particular-
ly for novel and more complex metabolomic diagnostics, and we emphasise this as an important area to 
focus on with regards to health system strengthening [3,6,45,46].
Our data also reinforces the fact that parental consanguinity plays an important role in the incidence of 
IEM, focused particularly in certain areas of the world [7,44]. Although often socioculturally complex, 
interventions to tackle this at a community level could play an important role in decreasing the number 
of births with IEM globally [47].
Treatment approaches for IEM are another essential area of focus. Emerging therapeutics including the use 
of molecular chaperones and substrate synthesis inhibitors show promising initial results, however due to 
high cost, are likely to be out of reach of many areas globally for the foreseeable future [48,49]. Despite 
this, the potential for extending existing management strategies employed in high-income settings to low-
er resourced populations has much potential to impact on global IEM morbidity and mortality [50]. In 
LMICs where access to paediatric endocrinology expertise is often limited or non-existent, even with an 
accurate diagnosis of an IEM, appropriate management can be difficult to provide [50,51]. The develop-
ment and propagation of clear national and international protocols for managing IEM and associated met-
abolic crises could provide one avenue of improving the standard of care for this important patient group.
CONCLUSIONS
IEM represent an important cause of global child morbidity and mortality, comprising a significant pro-
portion of child deaths which are as of yet poorly described in global modelling efforts. Although more 
population-level research is required to further establish the epidemiology of these conditions, our study 
emphasises several areas for current policy focus, including enhanced laboratory capacity for screening 
and diagnosis, community interventions to tackle parental consanguinity, and dissemination of knowl-
edge regarding awareness and management of these important conditions.
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